Shares of CeriBell (NASDAQ:CBLL – Get Free Report) shot up 9.1% on Tuesday . The company traded as high as $22.91 and last traded at $22.95. 113,825 shares changed hands during trading, a decline of 46% from the average session volume of 210,938 shares. The stock had previously closed at $21.04.
Analyst Upgrades and Downgrades
Several equities research analysts have commented on the company. TD Cowen boosted their target price on CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Canaccord Genuity Group upped their price target on shares of CeriBell from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Bank of America initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $32.00 price objective on the stock. William Blair started coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an “outperform” rating for the company. Finally, Canaccord Genuity Group started coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $30.00 price target for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $32.60.
Check Out Our Latest Stock Analysis on CeriBell
CeriBell Price Performance
CeriBell (NASDAQ:CBLL – Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The firm had revenue of $17.20 million for the quarter, compared to analysts’ expectations of $17.06 million. Analysts anticipate that CeriBell will post -2.46 earnings per share for the current year.
About CeriBell
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Articles
- Five stocks we like better than CeriBell
- What Are Dividends? Buy the Best Dividend Stocks
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- Following Congress Stock Trades
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
